Mirum Pharmaceuticals (MIRM)

• Market cap: $6.46B
• 1 day: -5.9%
• 5 days: -7.99%
• 1 month: -9.5%
• 3 months: 8.88%
• 6 months: 2.07%
• Year to date: 35.71%
• 1 year: 105.01%
• 5 years: 612.03%
• 10 years: 702.04%
• Sector: Healthcare
• Industry: Biotechnology

About: Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.

Employees: 418